Novel nano-pomegranates based on astragalus polysaccharides for targeting ERα-positive breast cancer and multidrug resistance. (1st January 2020)

• Record Type: Journal Article
• Authors: Wang, Bingjie; Guo, Chunjing; Liu, Yanhui; Han, Guangting; Li, Yi; Zhang, Yanchun; Xu, Haiyu; Chen, Daquan
• Is Part Of: Drug delivery. Volume 27:Number 1(2020)
• Page Start: 607
• Page End: 621
• Publication Date: 2020-01-01
• Subjects: Astragalus polysaccharides -- targeting ERα-positive breast cancer -- multidrug resistance -- nano-pomegranates; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2020.1754529
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Chemotherapy is an important method for treating breast cancer. However, multidrug resistance is one of the major challenges in breast cancer chemotherapy. There is an urgent need to develop novel, effective antitumor strategies that will perfect existing therapeutic regimens. In this study, the double-targeted nanocarrier, Quercetin-3'3-dithiodipropionic acid-Astragalus polysaccharides-Folic acid (QDAF), was successfully synthesized and self-assembled into a neoteric nano-targeted delivery strategy, named nano-pomegranates, and which were utilized to effectively inhibit multidrug resistance in estrogen receptor α (ERα)-positive breast tumor. The outstanding abilities of nano-pomegranates to release the drug in a reducing environment was determined by in vitro release assay. The cellular studies in MCF-7 cells were examined that nano-pomegranates have remarkable efficiencies of enhancing cellular uptake, inhibition and necrosis and apoptosis. In vivo antitumor experiments showed that nano-pomegranates have better anti-tumor effects and lower systemic toxicity than free Cur. In conclusion, nano-pomegranates have great potential in anti-breast cancer treatment.